Obesity, orforglipron reduces estimated risk of diabetes and cardiovascular disease
SESTO FIORENTINO (ITALPRESS) – Eli Lilly and Company, the producer of tirzepatide, announced the results of the post-hoc analysis of the ATTAIN-1 study, according to which orforglipron is associated with significant reductions of the risk predicted to 10 years of […]
Obesity, orforglipron reduces estimated risk of diabetes and cardiovascular disease Read More »










